The net profits after tax of Memphis Pharmaceutical and Chemical Industries jumped by 9% year-on-year to EGP 152.965 million in the first quarter (Q1) of fiscal year (FY) 2025/2026

Memphis Pharmaceutical and Chemical Industries reported a 164% year-on-year leap in net profits after tax in the fiscal year (FY) 2024/2025, according to the firm’s financial indicators.

Memphis Pharmaceutical’s board approved the estimated budget for fiscal year (FY) 2025/2026, targeting net profits after tax valued at EGP 300 million

Memphis Pharmaceutical recorded 125.9% year-on-year (YoY) higher net profits after tax at EGP 375.756 million in the first nine months of fiscal year (FY) 2024/25

Memphis Pharmaceutical (MPCI) saw a 223% year-on-year (YoY) surge in its net profits after tax during the first half (H1) of fiscal year (FY) 2024/2025.

The Financial Regulatory Authority (FRA) has approved publishing the disclosure form submitted by Memphis Pharmaceutical and Chemical Industries’ board to invite senior shareholders to subscribe to the company’s remaining rights issue.

Memphis Pharmaceutical and Chemical Industries reported a 112% year-on-year increase in net profits after tax in the fiscal year (FY) 2023/2024.

Memphis Pharmaceutical and Chemical Industries’ first phase of capital increase subscription has been covered by 93.78% at a total value of EGP 160.601 million.

The Egyptian Exchange’s (EGX) listing committee has approved listing an increase of EGP 171.25 million for Memphis Pharmaceutical and Chemical Industries, as per a disclosure.

Memphis Pharmaceutical and Chemical Industries reported a 115% year-on-year increase in net profits after tax in the fiscal year (FY) 2023/2024.

The Financial Regulatory Authority (FRA) has approved in principle for Memphis Pharmaceutical and Chemical Industries to invite senior shareholders to subscribe to the company’s rights issue.

Memphis Pharmaceutical and Chemical Industries has reported a 374.5% annual surge in its net profits after tax in the first nine months of the fiscal year (FY) 2023/2024, according to the firm’s unaudited income statement released on April 29th.

Memphis Pharmaceutical (MPCI) saw a 201% year-on-year (YoY) surge in its net profits after tax during the first half (H1) of fiscal year (FY) 2023/2024.

Memphis Pharmaceutical and Chemical Industries has announced the payment of EGP 2 per share in cash dividends to shareholders for fiscal year (FY) 2022/2023 as of November 9th.

Memphis is one of the oldest pharmaceutical and chemical companies in the Middle East and has been in the market since 1940.

Memphis Pharmaceutical and Chemical Industries has reported a 19% year-on-year (YoY) increase in net profits after tax in the fiscal year (FY) 2022/2023.

Memphis Pharmaceutical and Chemical Industries’ board has approved the estimated budget for the fiscal year (FY) 2023/2024 with expected net profits after tax of EGP 104.200 million.

Memphis earned revenues of EGP 440.465 million during the period from July 2022 to March 2023, signaling an 8.4% year-on-year (YoY) increase from EGP 406.512 million over the same period of the FY before.